.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Role for rexinoids is expanding

April 1, 2004

Waikoloa, Hawaii - Rexinoids such as bexarotene have promise as an adjunct to other immune response modifiers in the treatment of patients with progressive cutaneous T-cell lymphoma (CTCL), according to Jacqueline M. Junkins-Hopkins, M.D. Such therapies are typically used in combination with interferon-alpha as well as with psoralen ultraviolet-A (PUVA) and extracorporeal photopheresis (ECP).